GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » 10x Genomics Inc (NAS:TXG) » Definitions » Beneish M-Score
中文

10x Genomics (10x Genomics) Beneish M-Score : -3.59 (As of Apr. 25, 2024)


View and export this data going back to 2019. Start your Free Trial

What is 10x Genomics Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.59 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for 10x Genomics's Beneish M-Score or its related term are showing as below:

TXG' s Beneish M-Score Range Over the Past 10 Years
Min: -4.17   Med: -3.26   Max: -1.99
Current: -3.59

During the past 7 years, the highest Beneish M-Score of 10x Genomics was -1.99. The lowest was -4.17. And the median was -3.26.


10x Genomics Beneish M-Score Historical Data

The historical data trend for 10x Genomics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

10x Genomics Beneish M-Score Chart

10x Genomics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial - -4.17 -1.99 -2.92 -3.59

10x Genomics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.92 -3.10 -2.91 -3.22 -3.59

Competitive Comparison of 10x Genomics's Beneish M-Score

For the Health Information Services subindustry, 10x Genomics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


10x Genomics's Beneish M-Score Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, 10x Genomics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where 10x Genomics's Beneish M-Score falls into.



10x Genomics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of 10x Genomics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9197+0.528 * 1.1592+0.404 * 0.7425+0.892 * 1.1981+0.115 * 0.7496
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9606+4.679 * -0.248248-0.327 * 1.0363
=-3.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $114.8 Mil.
Revenue was 183.979 + 153.644 + 146.819 + 134.285 = $618.7 Mil.
Gross Profit was 115.782 + 95.529 + 99.612 + 98.39 = $409.3 Mil.
Total Current Assets was $596.0 Mil.
Total Assets was $965.1 Mil.
Property, Plant and Equipment(Net PPE) was $344.9 Mil.
Depreciation, Depletion and Amortization(DDA) was $43.6 Mil.
Selling, General, & Admin. Expense(SGA) was $343.3 Mil.
Total Current Liabilities was $127.2 Mil.
Long-Term Debt & Capital Lease Obligation was $83.8 Mil.
Net Income was -48.952 + -92.986 + -62.414 + -50.747 = $-255.1 Mil.
Non Operating Income was 3.961 + -1.248 + -1.504 + -1.516 = $-0.3 Mil.
Cash Flow from Operations was 25.758 + -25.304 + -11.526 + -4.125 = $-15.2 Mil.
Total Receivables was $104.2 Mil.
Revenue was 156.232 + 131.072 + 114.609 + 114.496 = $516.4 Mil.
Gross Profit was 119.405 + 100.695 + 86.905 + 89.018 = $396.0 Mil.
Total Current Assets was $635.0 Mil.
Total Assets was $1,029.0 Mil.
Property, Plant and Equipment(Net PPE) was $359.2 Mil.
Depreciation, Depletion and Amortization(DDA) was $33.0 Mil.
Selling, General, & Admin. Expense(SGA) was $298.3 Mil.
Total Current Liabilities was $131.0 Mil.
Long-Term Debt & Capital Lease Obligation was $86.1 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(114.832 / 618.727) / (104.211 / 516.409)
=0.185594 / 0.201799
=0.9197

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(396.023 / 516.409) / (409.313 / 618.727)
=0.766879 / 0.661541
=1.1592

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (596.022 + 344.932) / 965.143) / (1 - (635.035 + 359.21) / 1028.98)
=0.025063 / 0.033757
=0.7425

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=618.727 / 516.409
=1.1981

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(33.006 / (33.006 + 359.21)) / (43.619 / (43.619 + 344.932))
=0.084153 / 0.112261
=0.7496

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(343.33 / 618.727) / (298.3 / 516.409)
=0.554897 / 0.577643
=0.9606

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((83.849 + 127.162) / 965.143) / ((86.139 + 130.957) / 1028.98)
=0.218632 / 0.210982
=1.0363

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-255.099 - -0.307 - -15.197) / 965.143
=-0.248248

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

10x Genomics has a M-score of -3.59 suggests that the company is unlikely to be a manipulator.


10x Genomics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of 10x Genomics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


10x Genomics (10x Genomics) Business Description

Traded in Other Exchanges
Address
6230 Stoneridge Mall Road, Pleasanton, CA, USA, 94588
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Executives
Serge Saxonov director, 10 percent owner, officer: Chief Executive Officer 10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94588
James Wilbur officer: Chief Commercial Officer C/O 10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94588-3260
Benjamin J. Hindson director, officer: See Remarks 10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94588
Justin J. Mcanear officer: Chief Financial Officer 10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94588
John R Stuelpnagel director 10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94588
Mathai Mammen director THERAVANCE,INC., 901 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Bradford Crutchfield officer: Chief Commercial Officer 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94547
Sridhar Kosaraju director 1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Bryan E Roberts director C/O VENROCK ASSOCIATES, 2494 SAND HILL ROAD STE 200, MENLO PARK CA 94025
Venrock Management Vi, Llc 10 percent owner 3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Venrock Associates Vi, L.p. 10 percent owner 3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Venrock Partners Vi, L.p. 10 percent owner 3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Venrock Partners Management Vi, Llc 10 percent owner 3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Foresite Capital Fund I, L.p. 10 percent owner 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Paladin Capital Management, Llc 10 percent owner 2020 K STREET, NW, SUITE 620, WASHINGTON DC 20006